Table 6.

Incremental cost-effectiveness ratio for different cost specifications of hospitalisation in 1000 DKK

Disc. rate	Scenario	Direct costs
		Costs per life-year gained			Costs per QALY gained (SMR=1, qCM=1)
		Specification 1	Specification 2	Specification 3	Specification 1	Specification 2	Specification 3
	(0%; 25%)	45–99	36–90	53–107	53–118	43–107	64–128
0%	(15%; 25%)	274–688	262–676	283–698	319–803	306–789	331–814
	(0%; 25%)	51–113	41–103	61–123	61–135	49–123	73–147
2%	(15%; 25%)	397–997	379–979	410–1010	460–1156	440–1136	476–1172
	(0%; 25%)	57–127	46–116	69–138	69–152	55–138	82–166
4%	(15%; 25%)	548–1376	524–1352	567–1395	605–1521	579–1495	626–1542
		Direct costs and productivity loss
	(0%; 25%)	0–88	0–79	69–97	0–105	0–94	0–115
0%	(15%; 25%)	60–474	52–462	69–483	72–553	62–539	82–564
	(0%; 25%)	67–101	58–91	76–111	80–129	69–108	91–132
2%	(15%; 25%)	86–686	69–669	100–700	100–796	80–776	116–812
	(0%; 25%)	73–113	64–102	83–125	88–135	76–122	100–149
4%	(15%; 25%)	119–948	95–924	138–967	132–1047	105–1021	153–1068

The intervals describe the ranges for the vaccination price including administration costs in the interval 300–500 DKK

DKK Danish kroner, QALY quality-adjusted life year, qCM comorbidity on quality of life, SMR standard mortality rate